Fresenius Secures FDA and EMA Review of Vedolizumab Biosimilar Candidate
The German healthcare giant's biosimilar application moves forward in both US and European markets, targeting a competitor to the reference drug Entyvio.
Regulatory Milestone for Biosimilar Portfolio
Fresenius SE & Co. KGaA announced Friday that its operating unit Fresenius Kabi has achieved regulatory acceptance on both sides of the Atlantic for its vedolizumab biosimilar candidate. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed biosimilar to the reference product Entyvio (vedolizumab).
The acceptance by both agencies marks a significant procedural step, triggering formal regulatory review processes that will assess the biosimilar's comparability to the reference biologic in terms of safety, efficacy, and quality.
Market Context
Vedolizumab, marketed as Entyvio, is a biologic therapy used to treat inflammatory bowel diseases including ulcerative colitis and Crohn's disease. The biosimilar market represents a strategic growth avenue for pharmaceutical companies as patents on originator biologics expire, offering opportunities to provide more cost-effective treatment alternatives.
For Fresenius, with a market capitalization of approximately $29 billion and shares closing at €44.88 prior to the announcement, the biosimilar pipeline represents an important component of its broader pharmaceutical strategy under the Fresenius Kabi division.
Looking Ahead
The regulatory review timelines for biosimilar applications typically span several months, with approval contingent on the agencies' assessment of comprehensive clinical and manufacturing data. According to MarginX data, Fresenius is scheduled to report its second-quarter 2026 results on August 5, where management may provide additional commentary on its biosimilar development strategy and pipeline progress.
The company is also slated to participate in the 15th Baader Investment Conference in mid-September, providing another forum for investor updates. Broader market conditions may be influenced by the Federal Reserve's rate decision scheduled for September 16.
The announcement underscores Fresenius Kabi's continued investment in complex generics and biosimilars, segments that have become increasingly competitive as pharmaceutical companies seek to diversify revenue streams and address healthcare cost pressures globally.
This article was generated by MarginX from public news on 2026-07-31. It is not investment advice.